泰地罗新

中文名称:

泰地罗新

中文同义词:

泰地罗新;泰地罗新 >95% BY HPLC;泰地罗新溶液,100PPM;TILDIPIROSIN泰地罗新

英文名称:

Tildipirosin

英文同义词:

tildipirosin;20-Deoxo-23-deoxy-5-O-[3,6-dideoxy-3-(dimethylamino)-beta-D-glucopyranosyl]-20,23-di-1-piperidinyltylonolide;Tildipirosin Solution, 100ppm;TIP; TILDIPIROSIN; ZUPREVO.;Zuprevo.;20-Deoxo-23-deoxy-5-O-[3,6-dideoxy-3-(dimethylamino)-beta-D-glucopyranosyl]-20,23-di-1-piperidinylty;Tylonolide, 20-deoxo-23-deoxy-5-O-[3,6-dideoxy-3-(dimethylamino)-β-D-glucopyranosyl]-20,23-di-1-piperidinyl-;Tildipirosin USP/EP/BP

CAS号:

328898-40-4

分子式:

C41H71N3O8

分子量:

734.02

EINECS号:

相关类别:

医药原料;化工原料;原料药;医用原料;产品;微生物代谢物;兽药原料药;医用原料;原料;医药、农药及染料中间体

Mol文件:

328898-40-4.mol

沸点 

846.8±65.0 °C(Predicted)

密度 

1.15

酸度系数(pKa)

13.18±0.70(Predicted)

概述

泰地罗新(Tildipirosin)是一种新型动物专用十六元环大环内酯类半合成抗生素，最早是由英特威国际有限公司（IntervetInternationalBV）开发的，为泰乐菌素的衍生物。

应用

泰地罗新是广谱抗菌药，对一些革兰氏阳性和革兰氏阴性细菌均有较强的抗菌活性，对引起猪、牛呼吸系统疾病的病原菌尤其敏感。

用途

泰地罗新是广谱抗菌药，对一些革兰氏阳性和革兰氏阴性细菌均具有抗菌活性，对引起猪、牛呼吸系统疾病的病原菌尤其敏感，如胸膜肺炎放线杆菌、多杀性巴氏杆菌、支气管败血波氏杆菌、副猪嗜血杆菌以及溶血性曼海姆菌、睡眠嗜组织菌等。

生物活性

Tildipirosin是一种半合成的大环内脂类抗菌素。

体外研究

Tildipirosin exhibits the inhibitory effect on C. coli species, and 23 of 31 (74%) isolates have MICs of 8 or 16 μg/mL while 8 of 31 (26%) have MIC >256 μg/mL. MICs against C. jejuni are 8-64 μg/mL. Tildipirosin against S. enterica and E. coli are 2-8 μg/mL. Tildipirosin inhibits the treponeme isolates form from CODD lesions from 19 sheep, with MIC90 of 0.0469 mg/L. The P. multocida B130 clones show the MIC of 0.25 mg/L for tildipirosin. The 10 P. multocida isolates that carry only erm(42) exhibit MIC of 16-32 mg/L for tildipirosin. The single M. haemolytica that harbours only erm(42) shows MIC of 32 mg/L for tildipirosin.

体内研究

The mean percentage of lung consolidation for tildipirosin (4 mg/kg, s.c.)-treated calves is significantly lower than those for tulathromycin-treated and control calves. Metaphylactic administration of tildipirosin to calves 5 days prior to H somni challenge prevents subsequent culture of the pathogen from bronchial secretions and is more effective in minimizing clinical disease and lung lesions than is metaphylactic administration of tulathromycin.